Related Experiment Video

Updated: Apr 28, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis

Ying Wu1, Hong-Bing Liu1, Xue-Fei Shi1

  • 1Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

Plos One
|June 14, 2014
PubMed
Abstract

Insights

Metformin may lower lung cancer risk in diabetic patients, while insulin use might increase it. Further research is needed to confirm these associations, especially considering smoking adjustments.

Area of Science:

  • Oncology
  • Endocrinology
  • Epidemiology

Background:

  • Growing evidence links hypoglycemic agents to lung cancer risk in diabetic individuals.
  • The specific impact of conventional agents like metformin, sulfonylureas, thiazolidinediones (TZDs), and insulin on lung cancer incidence requires further clarification.
  • Understanding these associations is crucial for managing comorbidities in diabetes patients.

Purpose of the Study:

  • To conduct a meta-analysis evaluating the relationship between common hypoglycemic agents and lung cancer risk in patients with diabetes.
  • To synthesize findings from randomized controlled trials (RCTs), cohort studies, and case-control studies.
  • To assess the influence of metformin, sulfonylureas, TZDs, and insulin on lung cancer incidence.

Main Methods:

  • A comprehensive meta-analysis was performed using data from EMBASE, MEDLINE, and Web of Science.
  • Included studies published up to October 2013, encompassing RCTs, cohort, and case-control designs.
  • Fixed and random effects models were employed to calculate summary odds ratios (ORs) with 95% confidence intervals (CIs), and the GRADE approach assessed evidence quality.

Main Results:

  • Metformin use was associated with a 15% reduction in lung cancer risk (OR 0.85, 95% CI 0.77-0.92), though not consistently in smoking-adjusted analyses.
  • Sulfonylurea and TZD use did not show significant associations with altered lung cancer risk.
  • Insulin use was linked to a higher lung cancer risk (OR 1.23, 95% CI 1.10-1.35), but RCT data did not yield statistically significant results.

Conclusions:

  • Metformin may offer a potential reduction in lung cancer risk for individuals with diabetes.
  • Insulin therapy might be associated with an increased risk of lung cancer in diabetic patients.
  • The observed effects require cautious interpretation, particularly due to inconsistencies in smoking-adjusted analyses and lack of statistical significance in RCTs.

More Related Videos

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes08:30

Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes

Published on: March 15, 2018

13.7K
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

1.2K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
27
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
949
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.9K